Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR mutation + BRAF V600E
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
;
673
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR mutation + BRAF V600E
Non Small Cell Lung Cancer
EGFR mutation + BRAF V600E
Non Small Cell Lung Cancer
trametinib + osimertinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + osimertinib + dabrafenib
Sensitive
:
C3
trametinib + osimertinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + osimertinib + dabrafenib
Sensitive
:
C3
EGFR mutation + BRAF V600E
Colorectal Cancer
EGFR mutation + BRAF V600E
Colorectal Cancer
cetuximab + alpelisib + encorafenib
Resistant: C3 – Early Trials
cetuximab + alpelisib + encorafenib
Resistant
:
C3
cetuximab + alpelisib + encorafenib
Resistant: C3 – Early Trials
cetuximab + alpelisib + encorafenib
Resistant
:
C3
EGFR mutation + BRAF V600E
Colorectal Cancer
EGFR mutation + BRAF V600E
Colorectal Cancer
cetuximab + binimetinib + encorafenib
Resistant: C3 – Early Trials
cetuximab + binimetinib + encorafenib
Resistant
:
C3
cetuximab + binimetinib + encorafenib
Resistant: C3 – Early Trials
cetuximab + binimetinib + encorafenib
Resistant
:
C3
EGFR mutation + BRAF V600E
Colorectal Cancer
EGFR mutation + BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Resistant: C3 – Early Trials
cetuximab + encorafenib
Resistant
:
C3
cetuximab + encorafenib
Resistant: C3 – Early Trials
cetuximab + encorafenib
Resistant
:
C3
EGFR mutation + BRAF V600E
Lung Adenocarcinoma
EGFR mutation + BRAF V600E
Lung Adenocarcinoma
trametinib + erlotinib
Sensitive: D – Preclinical
trametinib + erlotinib
Sensitive
:
D
trametinib + erlotinib
Sensitive: D – Preclinical
trametinib + erlotinib
Sensitive
:
D
EGFR mutation + BRAF V600E
Lung Adenocarcinoma
EGFR mutation + BRAF V600E
Lung Adenocarcinoma
erlotinib
Resistant: D – Preclinical
erlotinib
Resistant
:
D
erlotinib
Resistant: D – Preclinical
erlotinib
Resistant
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login